Advances in the adjuvant treatment of colorectal cancer (Q36503798)

14 August 2017

1 reference

title

Advances in the adjuvant treatment of colorectal cancer (English)

1 reference

14 August 2017

1 reference

Ina C Nordman

1

1 reference

14 August 2017

Shoba Iyer

series ordinal

2

1 reference

14 August 2017

Anthony M Joshua

series ordinal

3

1 reference

14 August 2017

Stephen J Clarke

series ordinal

4

1 reference

14 August 2017

1 May 2006

1 reference

14 August 2017

ANZ Journal of Surgery

1 reference

14 August 2017

76

1 reference

14 August 2017

5

1 reference

14 August 2017

373-380

1 reference

Global cancer statistics in the year 2000.

14 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Incidence and patterns of recurrence following curative resection for colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma--long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Intervent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Capecitabine as adjuvant treatment for stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Targeted therapy with imatinib: hits and misses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Molecular staging for survival prediction of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Colorectal cancer prognosis: is it all mutation, mutation, mutation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Colorectal cancer patterns of care in the Western Sydney and Wentworth Area Health Services

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Microvessel quantification and its possible relation with liver metastasis in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Angiogenesis in normal tissue adjacent to colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-2197.2006.03726.X

10.1111/J.1445-2197.2006.03726.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference